Myeloma UK will attend the 2017 Health Technology Assessment International (HTAi) conference between 17 and 21 June in Rome.
The annual conference focuses on exchanging information, methods and expertise across stakeholders involved in national drug approval. It aims to drive the positive development of health technology assessment (HTA) across the globe.
HTAi is a not-for-profit organisation that promotes the best practice worldwide in HTA, a process used by national health systems to decide whether or not new drugs are made widely available to patients.
In the UK, HTA bodies include the National Institute for Health and Care Excellence (NICE) in England and Wales and the Scottish Medicines Consortium (SMC) in Scotland. You can find out more about HTA in our dedicated Infosheet.
As well as attending the event and participating in a range of workshops, Myeloma UK Health Services Research Manager, Dr Jayne Galinsky, will also present findings at HTAi from a patient preference survey conducted by Myeloma UK in collaboration with Dr Simon Fifer from Community and Patient Preference Research (CaPPRe).
Jayne said, “The aim of this survey was to enhance our understanding of what myeloma patients specifically want from treatments. It looked at specific areas, such as what aspects of treatment myeloma patients particularly value and the maximum risk they are willing to accept. This type of research is important as it could help inform future projects conducted around drug development in myeloma and promote a more patient-centred approach.”
She added, “Myeloma UK is committed to putting patients first, so it is great to be able to share our findings on this global stage. We are grateful to all patients who took part in our survey and look forward to presenting our findings.”
Attending HTAi is part of the work Myeloma UK does to bring myeloma patients access to the most promising treatments.
Myeloma UK Policy and Public Affairs Manager, Kate Morgan, will also attend HTAi. She added, “Conferences like HTAi allow the chance for all of us to hear from and speak to global experts and explore new ways to collaborate on improving HTA and the surrounding processes such as licensing and drug development.
“This in turn will feed back into our work with NICE and SMC to ensure myeloma patients across the UK have the best access to new and effective treatments.”